Genomic targets and associated agents available commercially or through ongoing clinical trials
| Target . | Genetic alteration . | Available agents . | Agents under investigation . | Active pediatric clinical trials . |
|---|---|---|---|---|
| FLT3 | FLT3-ITD | Midostaurin Sorafenib Gilteritinib | Gilteritninb Crenolanib Quizartinib | NCT04293562 NCT03793478 NCT04240002 |
| FLT3-TKD | Midostaurin Gilteritinib | Gilteritinib Crenolanib | NCT04293562 | |
| BCL2 | — | Venetoclax | Venetoclax Navitoclax Obatoclax | NCT03194932 NCT03826992 NCT03236857 NCT04898894 NCT05317403 |
| IDH | IDH1 | Ivosidenib | — | — |
| IDH2 | Enasidenib | Enasidenib | NCT04203316 | |
| MEK | NRAS KRAS PTPN11 NF1 CBL | Trametinib | Trametinib | NCT03190915 |
| Menin | KMT2Ar NPM1 NUP98 | — | SNDX-5613 KO-539 JNJ-75276617 DSP 5336 BMF-219 | NCT04065399 NCT05326516 |
| E-selectin | E-selectin ligand expression | — | Uproleselan | NCT05146739 |
| XPO1 | — | Selinexor | Selinexor | NCT04898894 |
| Target . | Genetic alteration . | Available agents . | Agents under investigation . | Active pediatric clinical trials . |
|---|---|---|---|---|
| FLT3 | FLT3-ITD | Midostaurin Sorafenib Gilteritinib | Gilteritninb Crenolanib Quizartinib | NCT04293562 NCT03793478 NCT04240002 |
| FLT3-TKD | Midostaurin Gilteritinib | Gilteritinib Crenolanib | NCT04293562 | |
| BCL2 | — | Venetoclax | Venetoclax Navitoclax Obatoclax | NCT03194932 NCT03826992 NCT03236857 NCT04898894 NCT05317403 |
| IDH | IDH1 | Ivosidenib | — | — |
| IDH2 | Enasidenib | Enasidenib | NCT04203316 | |
| MEK | NRAS KRAS PTPN11 NF1 CBL | Trametinib | Trametinib | NCT03190915 |
| Menin | KMT2Ar NPM1 NUP98 | — | SNDX-5613 KO-539 JNJ-75276617 DSP 5336 BMF-219 | NCT04065399 NCT05326516 |
| E-selectin | E-selectin ligand expression | — | Uproleselan | NCT05146739 |
| XPO1 | — | Selinexor | Selinexor | NCT04898894 |